高リスク家族のがん予防のためのウェブベースの家族支援プログラム
高リスク家族のがん予防のための、患者主導のセルフナビゲーション型ウェブベース家族支援プログラム
This trial develops a patient-driven self-navigated web-based family outreach program for cancer prevention in high-risk families. Creating the family outreach program may help to improve the way in which genetic test results are communicated within families and increase the number of at-risk relatives who become aware of their risks.
調査の概要
詳細な説明
PRIMARY OBJECTIVES:
I. To develop a secure, web-based program for family outreach in Clinical Cancer Genetics (CCG).
II. The long-term goals of this program are expected to include, but are not limited to the following:
IIa. To enable families with inherited cancer susceptibility and/or at increased familial risk of cancer to provide personal and family history of neoplasia through a convenient and self-directed program.
IIb. To enable communication of possible inherited cancer susceptibility with and among family members through the web-based portal.
IIc. To facilitate genetic testing, screening and prevention strategies in those at risk.
IId. Establish high-risk cohort for optional participation in research and clinical trials.
OUTLINE:
Patients communicate with at-risk family members to share genetic test results and other relevant information, as well as to learn more about their disease via family outreach program website. At risk family members are then contacted by a study coordinator or genetic counselor for further follow-up. At-risk relatives receive resources to facilitate understanding of their at-risk status and to facilitate predictive testing.
研究の種類
入学 (実際)
連絡先と場所
研究場所
-
-
Texas
-
Houston、Texas、アメリカ、77030
- M D Anderson Cancer Center
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Participants with genetic abnormalities and their families at MD Anderson Cancer Center in Houston, Texas
説明
Inclusion Criteria:
- Individuals who have been diagnosed with a hereditary cancer-causing mutation. Individuals may be identified through clinical testing as patients at MD Anderson or patients whose mutation was identified at an outside institution who contact the registry
- Individuals that have clinical suspicion for syndromic cancer susceptibility, but in whom mutational testing has been nondiagnostic (depending on condition in question, nondiagnostic testing may be as little as 10%, as in familial adenomatous polyposis [FAP], or as high as 70% in suspected hereditary diffuse gastric cancer or HDGC)
- At-risk family members of individuals with a cancer causing mutation or of individuals with nondiagnostic testing notwithstanding presence of likely syndromic cancer. Such patients will in most cases not be MD Anderson patients. Note: The enrollment, consenting, and evaluation process anticipates and addresses this.
Exclusion Criteria:
- Index patients who test negative for a cancer causing mutation, except for those agreeing to provide family history (FH) that is informative for at-risk individuals when no other source of such information is available
- Patients who are unwilling or are unable to provide informed consent
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:FAMILY_BASED
- 時間の展望:PROSPECTIVE
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Observational (family outreach program)
Patients communicate with at-risk family members to share genetic test results and other relevant information, as well as to learn more about their disease via family outreach program website. At risk family members are then contacted by a study coordinator or genetic counselor for further follow up. At-risk relatives receive resources to facilitate understanding of their at-risk status and to facilitate predictive testing. |
Ancillary studies Communicate via family outreach program website
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Web-Based Family Outreach Registry
時間枠:Continual assessment of data over participant's life time (target follow-up duration: 40 Years)
|
Data analysis for core functions of the web-based Family Outreach Registry will generally be descriptive. Web-based program to improve the way in which genetic test results are communicated within families and to increase the number of at-risk relatives who become aware of their risks. |
Continual assessment of data over participant's life time (target follow-up duration: 40 Years)
|
協力者と研究者
捜査官
- 主任研究者:Selvi Thirumurthi、M.D. Anderson Cancer Center
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (推定)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 2014-0715
- P30CA016672 (米国 NIH グラント/契約)
- 2014-0715 (その他の識別子:M D Anderson Cancer Center)
- NCI-2020-00567 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。